Grifols remains in a re-rating phase following its July earnings report, with a strong breakout from a six-month consolidation giving way to more cautious trading around €10.Following the H1 ...
Grifols shares remain in focus following the launch of its new drug FESILTY in the United States. However, as before, the key factor in evaluating the company is not only business growth but also ...
Grifols shares remain under pressure following a challenging two-year period, although the company's fundamental outlook is gradually improving. The business continues to grow earnings while ...